Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat

A prominent side effect of Paclitaxel chemotherapy is sensorimotor peripheral neuropathy. Leukaemia inhibitory factor (LIF) supports the survival and regrowth of axotomised sensory and motor neurons and we therefore investigated if systemically administered LIF abrogated Paclitaxel-induced neuropath...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Brain research 2001-08, Vol.911 (2), p.163-167
Hauptverfasser:	Kilpatrick, Trevor J, Phan, Si, Reardon, Katrina, Lopes, Elizabeth C, Cheema, Surindar S
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Phytogenic - pharmacology Axons - drug effects Axons - pathology Biological and medical sciences Calcitonin Gene-Related Peptide - metabolism Cell Count Chemotherapy Disease Models, Animal Dose-Response Relationship, Drug Drug Interactions - physiology Drug toxicity and drugs side effects treatment Ganglia, Spinal - drug effects Ganglia, Spinal - pathology Growth Inhibitors - pharmacology Immunohistochemistry Interleukin-6 Leukemia inhibitory Leukemia Inhibitory Factor Lymphokines - pharmacology Medical sciences Nerve Degeneration - chemically induced Nerve Degeneration - drug therapy Nerve Degeneration - physiopathology Neural Conduction - drug effects Neural Conduction - physiology Neurons, Afferent - drug effects Neurons, Afferent - pathology Neuropathy Paclitaxel Paclitaxel - pharmacology Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - drug therapy Peripheral Nervous System Diseases - physiopathology Pharmacology. Drug treatments Rats Rats, Wistar Substance P - metabolism Toxicity: nervous system and muscle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A prominent side effect of Paclitaxel chemotherapy is sensorimotor peripheral neuropathy. Leukaemia inhibitory factor (LIF) supports the survival and regrowth of axotomised sensory and motor neurons and we therefore investigated if systemically administered LIF abrogated Paclitaxel-induced neuropathy. We found that whereas animals administered Paclitaxel alone exhibited a significant decrease in the percentage of large myelinated axons, this reduction was prevented by the co-administration of LIF.
ISSN:	0006-8993 1872-6240
DOI:	10.1016/S0006-8993(01)02627-0